Abstracts tagged "DMARDs"

Abstract Number: 1285 • 2012 ACR/ARHP Annual Meeting
Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis
Roy Fleischmann¹, Andrew S. Koenig², Annette Szumski³, Henk Nab⁴, Lisa Marshall⁵ and Eustratios Bananis³, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Pfizer Europe, Rome, Italy, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: The objective of this study was to assess the short-term benefit of etanercept (ETN) + methotrexate (MTX) vs. various disease-modifying anti-rheumatic drugs (DMARDs; hydroxychloroquine…
Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting
Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early
Kavish J. Bhansing¹, Piet LCM Van Riel², Sigrid Pillen³, Baziel G.M. van Engelen⁴ and Madelon C. Vonk⁵, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Neurology, Catharina Wilhemina Hospital, Nijmegen, Netherlands, ⁴Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Glucocorticoids are the cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].